NASDAQ:AKRX Akorn (AKRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.09▼$0.3252-Week Range N/AVolume1.19 million shsAverage Volume9.60 million shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Akorn alerts: Email Address Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About Akorn Stock (NASDAQ:AKRX)Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.Read More Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. AKRX Stock News HeadlinesMay 15, 2023 | thestreet.comAkorn Reaches New 52-Week High (AKRX)October 20, 2022 | businesswire.comCarlin Consumer Health Names Scott Chapman Chief Executive Officer - Business WireJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.October 10, 2022 | prnewswire.comVeterinary Eye Care Market Size to record USD 788.78 Million Growth at a CAGR of 4.65% by 2026, Evolving Opportunities with Bausch Health Co Inc. And Akorn Operating Co. - Technavio - PR NewswireOctober 9, 2022 | fortune.comA small fund wagered that Elon Musk would be forced to buy Twitter—and made a killing by betting against the crowd - FortuneSeptember 29, 2022 | finance.yahoo.comDiuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio - Yahoo FinanceSeptember 15, 2022 | moodys.comMoody's downgrades Akorn to Caa2; revises outlook to stable from positive - Moody'sSeptember 2, 2022 | nasdaq.comPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well - NasdaqJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 29, 2022 | businesswire.comThe Worldwide Inhalation & Nasal Sprays Generic Drugs Industry is Expected to Reach $11.2 Billion by 2027 - ResearchAndMarkets.com - Business WireAugust 27, 2022 | fortune.comShort-sellers, lawyers, and academics predict the odds Elon Musk will be forced to close on a $44 billion deal he hates - FortuneAugust 26, 2022 | businesswire.comThe Worldwide Glaucoma Treatment Industry is Expected to Reach $9.1 Billion by 2027 - ResearchAndMarkets.com - Business WireAugust 26, 2022 | globenewswire.comConjunctivitis Market to Grow at a Healthy CAGR of 5.8% from 2022 to 2032 Owing to Growing Disease Prevalence Globally | Future Market Insights, Inc. - GlobeNewswireAugust 23, 2022 | law360.comWhistleblower Claims Rattle Twitter's Bid To Force Musk Deal - Law360August 17, 2022 | bloomberg.comAkorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg - BloombergAugust 16, 2022 | prnewswire.comAkorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg - PR NewswireAugust 11, 2022 | globenewswire.comPterygium Drug Market Trends, Shares, Key Players, Regional Overview and Market Is Growing At CAGR Of 6.2% By 2029 - GlobeNewswireAugust 5, 2022 | law360.comDelaware Powerhouse: Paul Weiss - Law360See More Headlines Receive AKRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AKRX CUSIP00972810 CIK3116 Webwww.akorn.com Phone847-279-6100FaxN/AEmployees2,227Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,770,000.00 Net Margins-55.64% Pretax MarginN/A Return on Equity8.53% Return on Assets1.31% Debt Debt-to-Equity Ratio0.09 Current Ratio0.50 Quick Ratio0.32 Sales & Book Value Annual Sales$682.43 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.19 Book Value$1.86 per share Price / BookN/AMiscellaneous Outstanding Shares133,152,000Free FloatN/AMarket Cap$3.60 million OptionableOptionable Beta0.95 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Duane A. Portwood (Age 53)Exec. VP & CFO Mr. Joseph Bonaccorsi (Age 54)Exec. VP, Gen. Counsel & Sec. Mr. Jonathan Kafer (Age 56)Exec. VP & Chief Commercial Officer Dr. Bruce Kutinsky (Age 53)Consultant Mr. Douglas S. Boothe (Age 55)Pres, CEO & Direcor Key CompetitorsEli Lilly and CompanyNYSE:LLYJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVPfizerNYSE:PFEView All Competitors AKRX Stock Analysis - Frequently Asked Questions How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) released its quarterly earnings results on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.45. The firm earned $204.69 million during the quarter, compared to analysts' expectations of $168.90 million. Akorn had a positive trailing twelve-month return on equity of 8.53% and a negative net margin of 55.64%. What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA). This page (NASDAQ:AKRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akorn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.